The Latest
-
Stock via Getty Images
The first new type of drug for Tourette syndrome in over 50 years is close to the FDA’s doorstep
Emalex Biosciences is full steam ahead with a targeted 2026 approval and launch for its novel drug.
-
Stock via Getty Images
Pricing transparency is in the spotlight — and that could be good news for drugmakers
An opaque system of rebates and discounts makes understanding a drug’s true price near impossible, even for experts. Can efforts to bring transparency into that system now pan out?
-
Permission granted by Biogen
What’s driving pharma’s layoffs in 2025
Familiar foes in the industry have claimed a slew of jobs in recent months.
-
iStock via Getty Images
As tariffs loom over pharma manufacturing, a reshoring effort is underway — but not without challenges
Experts say cost and other barriers present challenges to returning to U.S. shores.
-
Kayla Bartkowski via Getty Images
How will Makary lead FDA amid workforce cuts and RFK Jr.s’ influence?
With President Trump’s nominee for FDA commissioner in Senate confirmation hearings, his approach to workforce cuts and other policies is under scrutiny.
-
iStock via Getty Images
The time is ripe for pharma M&A. Why are drugmakers holding out?
The M&A resurgence has been predicted for years, but the industry is still holding out, partly because the ideal range for biotech valuations has been harder to find.
-
Kevin C. Cox via Getty Images
The top 3 impacts of Trump’s health data purge
Interrupted access to health-related data has already led to worse outcomes and could undermine faith in the U.S. healthcare system, experts say.
-
Permission granted by Voyager Therapeutics
New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach
Voyager Therapeutics’ progress with drug candidates targeting tau marks a step in how the industry is walking multiple paths toward new therapeutic options.
-
Mario Tama via Getty Images
With patent losses on the horizon, Amgen refocuses its business strategy
The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its “ambitious growth aspirations.”
-
Courtesy of AbbVie
AbbVie gets into obesity with $350M deal for once-weekly shot
A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.
-
Stock via Getty Images
Americans want to participate in clinical trials — so why don’t they?
A recent study revealed the key barriers to enrollment and how pharma can help turn the tide.
-
Courtesy of GSK Flickr page
How pharma CEO pay shifted for these 4 companies last year
Top executives saw big pay changes in a year defined by slower M&A and political uncertainty.
-
Permission granted by Teva
Teva targets schizophrenia to build on innovative medicines growth
The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.
-
Permission granted by Recursion
Q&AAI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration
Recursion CFO Ben Taylor discusses the state of AI M&A and what companies should look for as the industry moves to new data technologies and systems.
-
Stock via Getty Images
Its CEO died. The company scrapped a promising program. Now, for their 2nd act.
Terns Pharmaceuticals sees blockbuster promise for two potential best-in-class molecules in obesity and oncology.
-
Getty Images via Getty Images
Cancer vaccines have stumbled, but the approach is gaining new steam
The number of candidates in development has nearly doubled over the past 15 years.
-
George Clerk via Getty Images
Pfizer names Patrizia Cavazzoni, former top FDA official, as chief medical officer
Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida Habtezion.
-
Getty Images via Getty Images
Incentivizing rare disease R&D is getting tougher, but revamped policies could turn the tide
Orphan drug development has long been incentivized by government policy. But as the financial math shifts, so do the risks of bringing rare disease drugs to market.
-
Chip Somodevilla via Getty Images
Kennedy’s MAHA agenda is tackling ‘conflicts of interest’ — and could take aim at FDA adcomms
Health agency job cuts and a newly-established MAHA commission leave many unanswered questions about potential reforms and impact on drug approvals.
-
Stock via Getty Images
A look at Trump’s healthcare cuts — so far
How the federal workforce crackdown has impacted the agencies that oversee pharma and healthcare.
-
Sarah Silbiger via Getty Images
In FDA job cuts, experts see threat of far-reaching impact
"Any place that gets cut, it's going to have an impact, because there's not any spare personnel at FDA,” said former agency commissioner Robert Califf, of the layoffs.
-
Permission granted by Immunocore
Q&A // First 90 DaysLilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO
Travis Coy is using his Big Pharma bona fides to prioritize business development at the diversified and growing company.
-
Stock via Getty Images
Q&AMerck, Lilly launch manufacturing R&D consortium to help ‘bolster’ U.S. production
The Young Institute Pharmaceutical Manufacturing Consortium will research and develop new production technologies.
-
Drew Angerer via Getty Images
Challenges mount for vaccine makers
End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump administration.
-
Stock via Getty Images
Biotech SpotlightCRISPR’s cardio catch-all drives a biotech’s broad potential
Scribe Therapeutics hopes to prevent cardiometabolic diseases by targeting underlying causes with CRISPR technology.
